What question did this study set out to answer?

This research evaluates the access and prescribing practices of GLP-1 receptor agonists in youth with type 2 diabetes across pediatric diabetes centers.

June 13, 2026Diabetes

2917-LB: Prescribing Practices and Clinical Support for GLP-1 Receptor Agonists in Youth-Onset Type 2 Diabetes: Data from the T1DX QI Collaborative

View Full Paper

Ask AI

Bookmark

This research evaluates the access and prescribing practices of GLP-1 receptor agonists in youth with type 2 diabetes across pediatric diabetes centers.
2025 T1DX-QI annual survey was administered to member centers for data collection.
Descriptive analyses were conducted to summarize GLP-1 RA use, insurance coverage, access, and monitoring.
Responses were obtained from 42 pediatric centers regarding GLP-1 RA prescribing.
88% of centers reported GLP-1 RA coverage for privately insured youth with type 2 diabetes.
Only 31% of centers had structured follow-up protocols for monitoring patients prescribed GLP-1 RAs.
25 centers indicated that ≤50% of patients with youth-onset type 2 diabetes were prescribed GLP-1 RAs.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial assesses GLP-1 receptor agonist access and usage in youth-onset type 2 diabetes, suggesting areas for improvement.

Cite This Study

NAIK et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf62dfaef96ed7f057f9e https://doi.org/10.2337/db26-2917-lb

View Full Paper

Ask AI

Bookmark

2917-LB: Prescribing Practices and Clinical Support for GLP-1 Receptor Agonists in Youth-Onset Type 2 Diabetes: Data from the T1DX QI Collaborative

Key Points

Discussion

Implication

Cite This Study

2917-LB: Prescribing Practices and Clinical Support for GLP-1 Receptor Agonists in Youth-Onset Type 2 Diabetes: Data from the T1DX QI Collaborative

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider